SCA
CLVS

Stuart Chaussee & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Stuart Chaussee & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,675
Closed -$19K – 245
2021
Q1 		$19K Buy
+2,675
New +$17.9K 0.01% 82

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stuart Chaussee & Associates's CLVS Position: Q2 2021 in Review

Stuart Chaussee & Associates sold out of Clovis Oncology, Inc. (CLVS) in Q2 2021, closing a stake of 2,675 shares — an estimated $19K sold.

Stuart Chaussee & Associates first reported a position in CLVS in Q1 2021 and held it in 1 quarter. The position peaked at $19K in Q1 2021. 160 funds tracked by Wall St. Rank hold CLVS as of Q2 2021.

  • Stuart Chaussee & Associates reported no remaining Clovis Oncology, Inc. position as of Q2 2021 after selling out during the quarter.
  • Stuart Chaussee & Associates sold 2,675 Clovis Oncology, Inc. shares in Q2 2021, an estimated $19K.
  • Stuart Chaussee & Associates first reported a position in Clovis Oncology, Inc. in Q1 2021 and held it in 1 quarter.
  • Stuart Chaussee & Associates's Clovis Oncology, Inc. position peaked at $19K in Q1 2021.
  • 160 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2021.

Based on Stuart Chaussee & Associates's 13F filing for Q2 2021, filed 6 Aug 2021.